Navigation Links
Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
Date:11/11/2009

cs; the risk that the FDA may interpret data differently than we do, and the FDA's actions with respect to our BLA and whether the FDA determines to convene an advisory committee to review the BLA; progress on the commercialization efforts for PROVENGE, including the expansion of Dendreon's manufacturing capacity and other necessary infrastructure; success in the hiring of additional personnel to support business growth and expansion; the outcome of any pre-approval inspection of Dendreon's expanded manufacturing facility; our dependence on the efforts of third parties; our reliance on intellectual property protection; and requisite receipt of FDA licensure for marketing of PROVENGE and the risk that additional capital could be needed in the future to fund additional required clinical trials or for the potential commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

                    DENDREON CORPORATION
            CONSOLIDATED STATEMENTS OF OPERATIONS
           (in thousands, except per share amounts)

                                 Three months ended       Nine months ended
                                    September 30,            September 30,
                                 ------------------       -----------------
                          
'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Completes Submission of Biologics License Application for PROVENGE
2. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
5. Dendreon Reports Second Quarter 2009 Financial Results
6. Dendreon Signs Lease for New Manufacturing Facility in Atlanta
7. Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
8. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
9. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
10. Dendreon Announces Closing of Common Stock Offering
11. Dendreon Announces Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... electronic age rests on our ability to control how ... through circuitry. Doing so requires particular precision, for applications ... that task falls to semiconductors. Now, a research ... and Applied Science and Arts and Sciences has shown ...
... April 8, 2011 VIGILAIR Systems, an ... instrumental in a newly published, and first of its ... patient Hospital Acquired Infections (HAI) with the application of ... Unit (NICU). The published article , Effect ...
... Calif., April 8, 2011 On April 12, at the ... and CEO of Marrone Bio Innovations (MBI), will ... an industry panel debating the topic of ,Feeding a Growing ... to curb environmental impact while producing enough food to feed ...
Cached Biology Technology:Penn research advances understanding of lead selenide nanowires 2Penn research advances understanding of lead selenide nanowires 3Newly Published Study Shows Dramatic Reduction in Hospital Acquired Infections 2Pam Marrone to Speak at Ag 2.0 Conference 2
(Date:7/9/2014)... Indiana state parks have helped restore the health of ... populations of white-tailed deer, a Purdue study shows. , ... of forest ecology, found that a 17-year-long Indiana Department ... parks has successfully spurred the regrowth of native tree ... , Jenkins said that while hunting may be ...
(Date:7/9/2014)... refers to species, selection for traits that are attractive ... selection enhances opportunities to mate, the tail of male ... University of California, Riverside have now found that sexual ... are linked. Describing the life histories of more ... the researchers found that species with placentas tend to ...
(Date:7/9/2014)... Rochelle, NY, July 9, 2014Biofuels derived from the oils ... to fossil fuels. To achieve this goal, optimization of ... in open pond systems, is needed. Sapphire Energy has ... of open pond algae cultivation systems, described in ... Liebert, Inc., publishers. The article is available on the ...
Breaking Biology News(10 mins):Hunting gives deer-damaged forests in state parks a shot at recovery 2Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Controlling contamination in open algae ponds for biofuels 2
... the helical, hairlike flagella that extend from their unicellular bodies. ... coli ) living in the human gut, have multiple flagella ... These cells turn somewhat acrobatically by unbundling their flagella, causing ... direction. But many microbes, including 90 percent of motile ...
... helped boost green foliage across the world,s arid regions ... CO2 fertilisation, according to CSIRO research., In findings based ... National University (ANU), found that this CO2 fertilisation correlated ... from 1982-2010 across parts of the arid areas studied ...
... donation is now one of the major reasons why ... trend may circumvent regulations at home or raise concerns ... the most controversial. Yet little is known about the ... - their characteristics, their motivation and their compensation. ...
Cached Biology News:Buckling up to turn 2Buckling up to turn 3Buckling up to turn 4Deserts 'greening' from rising CO2 2Egg donation in European clinics: Why do women do it? 2Egg donation in European clinics: Why do women do it? 3
... Analyzer for superior sensitivity, mass accuracy, and resolving power., Specifications:, ... ion selection range: 150 - 4000 m/z, * Resolution: 14,000 (1400 ... * Dynamic range: 4 orders of magnitude ... ...
... M (OSM) is a pleiotropic cytokine produced ... sarcoma cells. OSM inhibits the growth of ... fibroblast, smooth muscle and Kaposis sarcoma cell ... low density lipoprotein receptor expression on hepatoma ...
... trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl ... latanoprost-related isomer containing both a double ... (β) hydroxyl group at C-15. Similar ... ester is a potential impurity in ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
Biology Products: